U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H33NO2
Molecular Weight 307.4715
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FINGOLIMOD

SMILES

CCCCCCCCc1ccc(cc1)CCC(CO)(CO)N

InChI

InChIKey=KKGQTZUTZRNORY-UHFFFAOYSA-N
InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3

HIDE SMILES / InChI
Fingolimod (FTY720) is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod (trade name Gilenya, Novartis) is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system. Fingolimod was approved as a first-in-class, orally active drug for relapsing multiple sclerosis in 2010, and its applications in other disease conditions are currently under clinical trials.

CNS Activity

Curator's Comment:: Fingolimod crosses the blood–brain barrier (BBB) and accumulates in the CNS.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
GILENYA

Approved Use

GILENYA is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. GILENYA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. (1)

Launch Date

1.28502714E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.65 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINGOLIMOD plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
149 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINGOLIMOD plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FINGOLIMOD plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
14 mg single, oral
Overdose
Dose: 14 mg
Route: oral
Route: single
Dose: 14 mg
Co-administed with::
phenoxymethylpenicillin(2000 mg, single)
Sources:
unhealthy, 33 years
n = 1
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 33 years
Sex: F
Population Size: 1
Sources:
Other AEs: Bradycardia, Hypotension...
Other AEs:
Bradycardia (1 patient)
Hypotension (1 patient)
Sources:
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Other AEs: Appendicitis, Urinary tract infection...
Other AEs:
Appendicitis (serious, 1 patient)
Urinary tract infection (serious, 1 patient)
Hyperlipidemia (10.9%)
Leukopenia (10.9%)
Lymphopenia (17.4%)
Constipation (4.3%)
Diarrhea (13%)
Stomatitis (13%)
Alanine aminotransferase increased (2.2%)
Aspartate aminotransferase increased (2.2%)
Cystitis (15.2%)
Bronchitis (4.3%)
Sources:
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources:
unhealthy, 37 years
n = 425
Health Status: unhealthy
Condition: relapsing remitting MS
Age Group: 37 years
Sex: M+F
Population Size: 425
Sources:
Disc. AE: Transaminases increased...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (3.8%)
Sources:
3.5 mg single, oral
Highest studied dose
Dose: 3.5 mg
Route: oral
Route: single
Dose: 3.5 mg
Sources:
unhealthy, 43.2 years
n = 3
Health Status: unhealthy
Age Group: 43.2 years
Sex: M+F
Population Size: 3
Sources:
Other AEs: Bradycardia, Carbon monoxide diffusing capacity decreased...
Other AEs:
Bradycardia (2 patients)
Carbon monoxide diffusing capacity decreased (1 patient)
Electrocardiogram T wave abnormal (1 patient)
Sources:
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Population Size: 6
Sources:
Other AEs: Chest tightness...
Other AEs:
Chest tightness (mild, 5 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Bradycardia 1 patient
14 mg single, oral
Overdose
Dose: 14 mg
Route: oral
Route: single
Dose: 14 mg
Co-administed with::
phenoxymethylpenicillin(2000 mg, single)
Sources:
unhealthy, 33 years
n = 1
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 33 years
Sex: F
Population Size: 1
Sources:
Hypotension 1 patient
14 mg single, oral
Overdose
Dose: 14 mg
Route: oral
Route: single
Dose: 14 mg
Co-administed with::
phenoxymethylpenicillin(2000 mg, single)
Sources:
unhealthy, 33 years
n = 1
Health Status: unhealthy
Condition: multiple sclerosis
Age Group: 33 years
Sex: F
Population Size: 1
Sources:
Hyperlipidemia 10.9%
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Leukopenia 10.9%
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Diarrhea 13%
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Stomatitis 13%
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Cystitis 15.2%
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Lymphopenia 17.4%
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Alanine aminotransferase increased 2.2%
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Aspartate aminotransferase increased 2.2%
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Bronchitis 4.3%
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Constipation 4.3%
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Appendicitis serious, 1 patient
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Urinary tract infection serious, 1 patient
1.25 mg 1 times / day steady, oral
Highest studied dose
Dose: 1.25 mg, 1 times / day
Route: oral
Route: steady
Dose: 1.25 mg, 1 times / day
Sources:
unhealthy, 36.0 years (range: 18–55 years)
n = 46
Health Status: unhealthy
Condition: relapsing multiple sclerosis
Age Group: 36.0 years (range: 18–55 years)
Sex: M+F
Population Size: 46
Sources:
Transaminases increased 3.8%
Disc. AE
0.5 mg 1 times / day multiple, oral
Recommended
Dose: 0.5 mg, 1 times / day
Route: oral
Route: multiple
Dose: 0.5 mg, 1 times / day
Sources:
unhealthy, 37 years
n = 425
Health Status: unhealthy
Condition: relapsing remitting MS
Age Group: 37 years
Sex: M+F
Population Size: 425
Sources:
Carbon monoxide diffusing capacity decreased 1 patient
3.5 mg single, oral
Highest studied dose
Dose: 3.5 mg
Route: oral
Route: single
Dose: 3.5 mg
Sources:
unhealthy, 43.2 years
n = 3
Health Status: unhealthy
Age Group: 43.2 years
Sex: M+F
Population Size: 3
Sources:
Electrocardiogram T wave abnormal 1 patient
3.5 mg single, oral
Highest studied dose
Dose: 3.5 mg
Route: oral
Route: single
Dose: 3.5 mg
Sources:
unhealthy, 43.2 years
n = 3
Health Status: unhealthy
Age Group: 43.2 years
Sex: M+F
Population Size: 3
Sources:
Bradycardia 2 patients
3.5 mg single, oral
Highest studied dose
Dose: 3.5 mg
Route: oral
Route: single
Dose: 3.5 mg
Sources:
unhealthy, 43.2 years
n = 3
Health Status: unhealthy
Age Group: 43.2 years
Sex: M+F
Population Size: 3
Sources:
Chest tightness mild, 5 patients
40 mg single, oral
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources:
unhealthy
n = 6
Health Status: unhealthy
Population Size: 6
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >900 uM]
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak [IC50 110 uM]
weak [IC50 12.5 uM]
weak [IC50 17 uM]
weak [IC50 180 uM]
weak [IC50 35 uM]
weak [IC50 36 uM]
weak [IC50 51 uM]
weak [IC50 53 uM]
weak [IC50 80 uM]
weak [IC50 80 uM]
yes [IC50 84 uM]
yes [IC50 9.9 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
minor [Km 107 uM]
unlikely (co-administration study)
Comment: Recombinant human CYP3A4, Vmax = 1423 pmol/(min.nmol CYP); Cyclosporine did not modify fingolimod overall exposure AUC(0-tz) or peak concentration (Cmax). The pharmacokinetics of steady-state cyclosporine were not altered during coadministration with singledose fingolimod.
Page: (ClinPharm) 11, 54, 55, 56-57, 207-210
minor [Km 73 uM]
no
yes [Km 117 uM]
yes [Km 76 uM]
Tox targets
PubMed

PubMed

TitleDatePubMed
Activation of caspases and mitochondria in FTY720-mediated apoptosis in human T cell line Jurkat.
2001 Oct
[mTOR and FTY 720 inhibitors].
2001 Sep 1
FTY720: a novel approach to the treatment of hepatic ischemia-reperfusion injury.
2002 Aug
Combined therapy of CTLA4Ig-gene transfection with FTY720 administration in rat lung allografts.
2002 Aug
T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2.
2002 Dec
Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice.
2002 Dec 27
A novel immunosuppressive drug, FTY720, prevents the cancer progression induced by cyclosporine.
2002 Jul 26
Combination treatment with FTY720 and CTLA4IgG preserves the respiratory epithelium and prevents obliterative disease in a murine airway model.
2002 Jun
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
2002 Jun 14
Donor pretreatment with FTY720 increases graft lymphocytes but does not affect graft survival following rat small bowel transplantation.
2002 May
Combined use of FTY720 and cyclosporine A prevents chronic allograft vasculopathy.
2002 May
Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses.
2002 May
Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.
2002 May 15
Effects of mycophenolate sodium with or without FTY720 in a DA-to-Lewis rat heart transplantation model.
2002 Nov
Sirolimus and FTY720: new approaches to transplant immunosuppression.
2002 Nov
FTY720 pretreatment reduces warm hepatic ischemia reperfusion injury through inhibition of T-lymphocyte infiltration.
2002 Oct
FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity.
2002 Oct
Transplantation.
2002 Oct
Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD.
2002 Oct 15
FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients.
2002 Sep
Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat.
2002 Sep 15
Renal transplantation: basic concepts and evolution of therapy.
2003
The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice.
2003 Apr
A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells.
2003 Apr
Immunosuppression with FTY720 and cyclosporine A inhibits rejection of adult porcine islet xenografts in rats.
2003 Apr 27
Current immunosuppressive agents: efficacy, side effects, and utilization.
2003 Dec
Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720.
2003 Dec 1
[Effects of three different immunosuppressive drugs on SD rat islet cell viability].
2003 Feb
FTY720: A new kid on the block for transplant immunosuppression.
2003 Jul
Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity.
2003 Jul-Aug
The effect of FTY 720 on engraftment in a model of spontaneous allograft acceptance.
2003 Jun
Elimination of cell-cycle regulators during caspase-3-dependent apoptosis caused by an immunosuppressant, FTY720.
2003 Mar
FTY720 stimulates multidrug transporter- and cysteinyl leukotriene-dependent T cell chemotaxis to lymph nodes.
2003 Mar
FTY720 reduces T-cell recruitment into murine intestinal allograft and prevents activation of graft-infiltrating cells.
2003 May 15
Significant prolongation of orthotopic corneal-graft survival in FTY720-treated mice.
2003 Nov 27
The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.
2003 Nov 6
[Study the mechanisms and inducing transplantation immune tolerance of FTY720].
2003 Oct
Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine.
2003 Oct
Egress: a receptor-regulated step in lymphocyte trafficking.
2003 Oct
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
2003 Oct 15
FTY720, a new immunosuppressant, as rescue therapy in mouse cardiac transplantation.
2003 Sep
Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.
2004 Apr 2
CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential.
2004 Jan
Pharmacologic immunosuppression.
2004 Jan 1
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.
2004 Jan 22
The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34+ progenitor cells.
2004 Jun 15
FTY720-induced lymphocyte homing modulates post-transplant preservation/reperfusion injury.
2004 Mar
FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors.
2004 Mar
The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors.
2004 Mar
Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.
2004 May
Patents

Sample Use Guides

The recommended dose of GILENYA is 0.5 mg orally once-daily. Fingolimod doses higher than 0.5 mg are associated with a greater incidence of adverse reactions without additional benefit. GILENYA can be taken with or without food.
Route of Administration: Oral
Astrocytes derived from human fetal CNS specimens and maintained in dissociated cultures were exposed to 100 nM of the biologically active form of Fingolimod (FTY720) over a dosing regimen that ranged from a single exposure (with or without washout after 1 h) to daily exposures up to 5 days, a single addition of FTY720 inhibited subsequent S1PR ligand-induced pERK1/2 signaling for >24 h. Daily FTY720 treatments (3-5 days) maintained this effect together with a loss of proliferative responses to the natural ligand S1P. Repeated FTY720 dosing concurrently maintained a functional cell response as measured by the inhibition of intracellular calcium release when stimulated by the cytokine IL-1β. Recurrent FTY720 treatments did not inhibit serum- or IL-1β-induced pERK1/2.
Name Type Language
FINGOLIMOD
DASH   INN   MART.   MI   ORANGE BOOK   VANDF   WHO-DD  
INN  
Official Name English
FTY-720
Code English
FTY720
Code English
FINGOLIMOD [MART.]
Common Name English
FINGOLIMOD [MI]
Common Name English
FINGOLIMOD [WHO-DD]
Common Name English
2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL
Systematic Name English
FINGOLIMOD [INN]
Common Name English
FINGOLIMOD [ORANGE BOOK]
Common Name English
1,3-PROPANEDIOL, 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)-
Systematic Name English
FINGOLIMOD [VANDF]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/09/718
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
LIVERTOX 412
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
WHO-VATC QL04AA27
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
NDF-RT N0000181816
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
NCI_THESAURUS C308
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
WHO-ATC L04AA27
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
FDA ORPHAN DRUG 305910
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
Code System Code Type Description
WIKIPEDIA
FINGOLIMOD
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
NCI_THESAURUS
C74202
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
INN
8341
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
EVMPD
SUB31908
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
RXCUI
1012892
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL314854
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
IUPHAR
2407
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
LACTMED
Fingolimod
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
DRUG BANK
DB08868
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
MESH
C098720
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
DRUG CENTRAL
4167
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
NDF-RT
N0000181815
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY Sphingosine 1-Phosphate Receptor Modulators [MoA]
PUBCHEM
107970
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
CAS
162359-55-9
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
EPA CompTox
162359-55-9
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY
MERCK INDEX
M5384
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY Merck Index
FDA UNII
3QN8BYN5QF
Created by admin on Sat Jun 26 09:38:56 UTC 2021 , Edited by admin on Sat Jun 26 09:38:56 UTC 2021
PRIMARY